Aryl-phenyl-sulfonamide compounds for inflammatory disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune disorders, such as rheumatoid arthritis, and bone-related diseases like osteoporosis, often have limitations including significant side effects, slow onset of action, and risk of disease rebound upon cessation, while existing therapies targeting TNFα and RANKL signaling may not fully address the underlying inflammatory and bone loss pathways effectively.
Innovation Solution
Development of aryl-phenyl-sulfonamido-phenylene compounds (APSAP compounds) that inhibit inflammatory responses, osteoclast activity, and bone resorption by blocking TNFα, IL-1, and RANKL signaling pathways, offering improved metabolic stability and aqueous solubility, thus providing a more effective and safer therapeutic option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and autoimmune disorders are used, then therapeutic effects are achieved, but significant side effects and risk of disease rebound occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of sulfonamide compounds to create novel aryl-phenyl-sulfonamido-phenylene derivatives with optimized pharmacological properties. These structural parameter changes result in compounds that maintain therapeutic efficacy while reducing adverse effects through improved selectivity and metabolic stability
Solution Approach 2:
The patent uses intermediaries by developing compounds that target specific molecular pathways (TNFα, IL-1, RANKL signaling) as mediators between the drug and the disease process. These compounds act as selective intermediaries that block pathological signaling while sparing normal physiological functions, thereby reducing side effects
2Reliability
If existing therapies targeting TNFα and RANKL signaling are used, then some inflammatory and bone loss pathways are addressed, but full effectiveness is not achieved
Solution Approach 1:
The patent applies universality by creating multi-functional compounds that simultaneously target multiple inflammatory and bone-related pathways (TNFα inhibition, IL-1 blocking, RANKL signaling interference). This multi-functionality allows a single compound to address multiple disease mechanisms, improving overall efficacy while simplifying treatment regimens
Solution Approach 2:
The patent merges multiple therapeutic functions into a single compound class by combining sulfonamide core structure with various aryl and phenylene substituents. This merging of functions (anti-inflammatory, anti-resorptive, immunomodulatory) into one agent achieves full effectiveness without requiring complex combination therapies
3Reliability
If metabolic stability and aqueous solubility are improved in APSAP compounds, then pharmacokinetic properties are enhanced, but compound structure becomes more complex
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the sulfonamide core structure to optimize local properties such as aqueous solubility and metabolic stability. These localized structural modifications (e.g., hydroxyl groups, fluorine atoms, specific alkyl chains) enhance pharmacokinetic properties without requiring complete structural redesign
Solution Approach 2:
The patent uses parameter changes by systematically varying molecular weight, logP values, and hydrogen bonding capacity through controlled substitution patterns. These parameter adjustments optimize the balance between solubility, stability, and potency, achieving enhanced pharmacokinetic properties through rational molecular design rather than random complexity
Data Source
AI summary
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.